Get started

ACAD

AUDCAD $AUDCAD - Apr. 18th, 2024AUDCAD OANDA:AUDCAD - Apr. 18th, 2024 BUY/LONG ZONE (GREEN): 0.88750 - 0.89550 DO NOT TRADE/DNT ZONE (WHITE): 0.88500 - 0.88750 SELL/SHORT ZONE (RED): 0.87850 - 0.88500 Weekly: DNT (at last week's close it was labeled bullish, with current momentum it's DNT) Daily: Bearish 4H: Bearish OANDA:AUDCAD has broken done into the next zone. This is what I would personally look at before entering trades, everything is subject to change on a daily basis and as I analyze different timeframes and ideas. EDUCATIONAL/ENTERTAINMENT PURPOSES ONLY, NOT FINANCIAL ADVICE! trendanalysis, trendtrading, priceaction, priceactiontrading, technical indicators, support and resistance, audcad, acad, aud, cad, GETTEX:AUD , LSE:CAD , OANDA:AUDCAD , forex, forexcurrency, forextrading, fx, fxpairs, fxaudcad, audcadtrend, audcadidea, audcadtrade, audcadsetup, audcadforecast, audcadlevel, audcadzone, audcadshort, audcadlong,
Short
by TonyAiello
#ACA BREAKOUT AND RETEST AND READY TO PUMP 60% !Hello, welcome to this ACA/USDT 4hr chart update by CRYPTOSANDERS. I have tried my best to bring the best possible outcome to this chart. Show some support do hit the like button, follow and comment in the comment section. this motivates me to bring this kind of chart analysis on regular basis. CHART ANALYSIS : #ACA/USDT As we can see in the above-mentioned chart that ACA just broke the triangle pattern and currently moving down to retest so at the green zone or the upper trend line we can take a long position for almost 60% in the upcoming days. Entry:- CMP and $1.490 Traget:- 60% Stoploss:- $1.37 Remember:-This is not a piece of financial advice. All investment made by me is at my own risk and I am held responsible for my own profit and losses. So, do your own research before investing in this trade. Happy trading. Sorry for my English it is not my native language. Do hit the like button if you like it and share your charts in the comments section. Thank you...
Long
by CryptoSanders9563
2
ACADIA Pharmaceuticals Inc 🧙Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ACADLong
by unfair_advantage
2
ACAD (ACADIA PHARMACEUTICALS INC) BUY ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low. Price should bounce and fill in the Gap in the market ACAD also filled its previous Buy gap from Sep 4th 2019 Title: Buy ACAD (ACADIA Pharmaceuticals) Asset: Stock Platform: Robinhood/WeBull/Etrade/ 401k account Symbol: ACAD Type: Buy Market Execution / Buy Limit Time Frame: 1D Entry Price 1: $26.50 ACTIVE Entry Price 2: $22.50(PENDING) Stop Loss: $19.50 (70 Pips) Take Profit 1: $33.00 (70 pips) Take Profit 2: $38.00 (140 pips) Take Profit 3: $44.00 (200 pips) Take Profit 4: $54.00 (300pips) Status: 🏃🏽‍♂️Active🏃🏽‍♂️ Sector: Health Technology Industry: Biotechnology ACADIA Pharmaceuticals operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R Brann on July 16, 1993 and is headquartered in San Diego CA
NASDAQ:ACADLong
by MavRich_Trading
3
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)buy ACAD entry 1 $44.50 & entry 2 $42.50 sl $38.50 tp.1 $50.50 tp.2 $55.50 Tp.3 $60.00 Tp.4 $70.50 Tp.5 $80.00 many products releasing soon Sector: Health Technology Industry: Biotechnology Employees: 503 ACADIA Pharmaceuticals , Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. Valuation Market Capitalization 8.373B Enterprise Value ( MRQ ) 5.922B Enterprise Value/EBITDA ( TTM ) — Total Shares Outstanding ( MRQ ) 155.861M Number of Employees 503 Number of Shareholders 26 Price to Earnings Ratio ( TTM ) — Price to Revenue Ratio ( TTM ) 22.1988 Price to Book (FY) 11.6201 Price to Sales (FY) 22.7131 Balance Sheet Quick Ratio ( MRQ ) 7.1997 Current Ratio ( MRQ ) 7.2630 Debt to Equity Ratio ( MRQ ) 0.0141 Net Debt ( MRQ ) -642.407M Total Debt ( MRQ ) 8.999M Total Assets ( MRQ ) 747.45M Operating Metrics Return on Assets ( TTM ) -0.3812 Return on Equity ( TTM ) -0.4504 Return on Invested Capital ( TTM ) -0.4450 Revenue per Employee ( TTM ) 674107.3559 Price History Average Volume (10 day) 1.571M 1-Year Beta 0.7491 52 Week High 58.7200 52 Week Low 21.5600 Dividends Dividends Paid (FY) 0 Dividends Yield (FY) 0 Dividends per Share (FY) 0 Margins Net Margin ( TTM ) -0.6499 Gross Margin ( TTM ) 0.9621 Operating Margin ( TTM ) -0.6784 Pretax Margin ( TTM ) -0.6485 Income Statement Basic EPS (FY) -1.5982 Basic EPS ( TTM ) -1.5783 EPS Diluted (FY) -1.5982 Net Income (FY) -235.259M EBITDA ( TTM ) -245.781M Gross Profit ( MRQ ) 86.899M Gross Profit (FY) 327.732M Last Year Revenue (FY) 339.076M Total Revenue (FY) 339.076M Free Cash Flow ( TTM ) -135.258M
NASDAQ:ACADLong
by MavRich_Trading
2
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)many products releasing soon Sector: Health Technology Industry: Biotechnology Employees: 503 ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. Valuation Market Capitalization 8.373B Enterprise Value (MRQ) 5.922B Enterprise Value/EBITDA (TTM) — Total Shares Outstanding (MRQ) 155.861M Number of Employees 503 Number of Shareholders 26 Price to Earnings Ratio (TTM) — Price to Revenue Ratio (TTM) 22.1988 Price to Book (FY) 11.6201 Price to Sales (FY) 22.7131 Balance Sheet Quick Ratio (MRQ) 7.1997 Current Ratio (MRQ) 7.2630 Debt to Equity Ratio (MRQ) 0.0141 Net Debt (MRQ) -642.407M Total Debt (MRQ) 8.999M Total Assets (MRQ) 747.45M Operating Metrics Return on Assets (TTM) -0.3812 Return on Equity (TTM) -0.4504 Return on Invested Capital (TTM) -0.4450 Revenue per Employee (TTM) 674107.3559 Price History Average Volume (10 day) 1.571M 1-Year Beta 0.7491 52 Week High 58.7200 52 Week Low 21.5600 Dividends Dividends Paid (FY) 0 Dividends Yield (FY) 0 Dividends per Share (FY) 0 Margins Net Margin (TTM) -0.6499 Gross Margin (TTM) 0.9621 Operating Margin (TTM) -0.6784 Pretax Margin (TTM) -0.6485 Income Statement Basic EPS (FY) -1.5982 Basic EPS (TTM) -1.5783 EPS Diluted (FY) -1.5982 Net Income (FY) -235.259M EBITDA (TTM) -245.781M Gross Profit (MRQ) 86.899M Gross Profit (FY) 327.732M Last Year Revenue (FY) 339.076M Total Revenue (FY) 339.076M Free Cash Flow (TTM) -135.258M
NASDAQ:ACADLong
by MavRich_Trading